Ketamine for Thrombolysis in Acute Ischemic Stroke

KETA trial is a nonprofit, double-blind, randomized, controlled pilot trial with aiming to determine if co-administration of ketamine with recombinant of tissue type plasminogen activator (tPA) for thrombolysis in acute ischemic stroke compared with tPA co-administered with placebo, decreases cerebral infarction growth in diffusion weighted imaging between admission and day 1. Eligibility applies to patients with symptomatic ischemic stroke seen within 4.5 h of onset with middle cerebral artery or distal internal carotid artery occlusion, no contraindication to intravenous tPA-mediated thrombolysis and eligible to endovascular treatment of stroke (i.e. thrombectomy). The study has been designed to have 80% power to detect a 80% decrease of infarct volume growth in the tPA-ketamine group at a two-sided type I error rate of 5%. For this purpose, at least 25 patients per arm should be enrolled.

Rationale - Tissue-type plasminogen activator (tPA) is a double-sided molecule, with beneficial effect in acute ischemic stroke due to its intravascular fibrinolytic activity but with potential deleterious effect due to its ability to potentiate neuronal N-methyl-D-aspartate (NMDA) receptor signalling (Nicole et al., 2001). Co-administration of sub-anesthetic dose of ketamine - a non-competitive inhibitor of NMDA receptor - was shown to improve efficacy of tPA-mediated thrombolysis following stroke in rodents (Gakuba et al, 2011).

Aims - To assess efficacy and safety of co-administration of ketamine with tPA compared with tPA-placebo infusion in patients with acute ischemic stroke.

Sample size estimates -With 25 patients per group, the trial has a 80% probability of detecting a 80% decrease of infarct volume growth in the tPA-ketamine group compared with the tPA-placebo group on day 1 after admission at a two-sided type I error rate of 5%.

Study outcomes - The primary efficacy outcome is cerebral infarction growth on diffusion weighted imaging between admission and day 1. The primary safety measure is mortality and/or symptomatic intracerebral hemorrhage rate at 3 months.

Eligibility Criteria:
Inclusion Criteria:

* Sudden focal neurological deficit attributable to acute ischemic stroke.
* Age between 18 and 85.
* Time from symptom onset less than 4.5 hours.
* NIHSS score between 7 and 20.
* Informed consent for participation.
* Ketamine can be administered within 15 minutes after onset of tPA infusion.
* MRI-based AIS diagnosis.
* Middle cerebral (M1 or M2 segment) and/or distal internal carotid artery occlusion.
* No intracranial hemorrhage on MRI.
* Patient eligible for thrombectomy.

Exclusion Criteria:

* Contraindication to IV tPA treatment.
* Contraindication to ketamine.
* Contraindication to MRI.
* Contraindication to intravascular iodinated contrast media.
* Consciousness level \>1 on question 1a of NIHSS.
* Pre-stroke mRS ≥3.
* Concomitant medical illness that would interfere with outcome assessments and follow-up (e.g. advanced cancer or respiratory disease).
* Previous participation in this trial or current participation in another investigational drug trial.
* Infarct volume on diffusion weighted MRI more than 100 mL.